Lubin Investment · Analyze · Screener · Compare

Fundamental analysis MEDP (Medpace Holdings Inc)

Updated on 07/31/2026

Method and analysis by Lubin Danilo, founder of Lubin Investment. Score computed automatically, with no human opinion.

We analyzed Medpace Holdings stock against the 10 quality criteria of Lubin Investment. The company gets a quality score of 10/10, meaning high quality, and a P/FCF valuation multiple of 23.5×.

Medpace Holdings is a quality company by our criteria, but the price does not follow: the free cash flow multiple stays high. A great company bought too expensively is still a poor investment, so this is typically one to watch while waiting for a better entry point.

Sector: Diagnostics & Research. Listing: US. Current price: 578.30 USD.

Lubin scoring methodology

Medpace Holdings Inc (MEDP)'s score is calculated automatically from 10 objective financial criteria, with no human intervention or opinion. Each criterion is validated (YES / PARTIAL / NO) based on thresholds drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran). The final score is the sum of validations.

The thresholds come from the financial literature, not from our preferences: see the valuation work of Aswath Damodaran (NYU Stern) and the SEC investor education resources (investor.gov).

Medpace Holdings's accounts are public: you can check every figure in its official 10-K filings with the SEC (EDGAR).

The 10 quantitative criteria analyzed

  1. Profitable: net margin > 5%
  2. Growing revenue: revenue growing > 10%/year over 5 years
  3. Growing earnings per share: FCF per share adjusted for stock-based compensation, > 10%/year over 5 years
  4. Share count under control: stable or declining (net buybacks = value creation for shareholders)
  5. Growing revenue per employee: revenue and revenue per employee both grow ≥ 10%/year over 5 years; partial when only one growth driver reaches its tier (fallback: free cash flow margin > 10% when employee history is unavailable)
  6. Expanding margins: operating margin widens over 5 years (operating leverage)
  7. Return on invested capital: Cash ROCE > 15% per year
  8. Debt under control: net debt repayable in less than 3 years of free cash flow
  9. Earnings converted to cash: free cash flow exceeds accounting net income
  10. Net collection period: short or negative cash conversion cycle

Its price against peers

Against the 5 other Diagnostics & Research stocks we have scored, Medpace Holdings trades at 23.5× its free cash flow, versus a median of 17.0× for that basket. On price alone, Medpace Holdings is therefore more expensive than its peers. That says nothing about its quality: at Lubin Investment, quality and price are judged separately, and a low multiple is only a bargain if the quality holds up.

Frequently asked questions

Is Medpace Holdings a quality stock?

Medpace Holdings gets a quality score of 10/10 (high quality), calculated over the 10 Lubin Investment criteria: profitability, revenue and free cash flow growth, share buybacks, margins, debt and return on capital.

How is Medpace Holdings's score calculated?

The score is the total of validated criteria (YES / PARTIAL / NO) using thresholds drawn from the financial literature (Warren Buffett, Mauboussin, Aswath Damodaran), automatically and with no human opinion.

What is Medpace Holdings's P/FCF?

The price-to-free-cash-flow (P/FCF) multiple of Medpace Holdings stock is 23.5×. At Lubin Investment, valuation is judged separately from quality.

Where to see Medpace Holdings's full analysis?

The full interactive analysis (10-criteria detail, history, P/FCF valuation, sector comparisons) is available at https://lubin-investment.com/analyse/MEDP?lng=en.

Articles about Medpace Holdings

Other stocks in the Diagnostics & Research sector

Go further

👉 See the full interactive analysis of MEDP

Other resources : All stocks in the Diagnostics & Research sector.